Top U.S. pharmaceutical patent expiries by revenue 2014-2016

Published by Statista Research Department, Dec 22, 2014
This statistic displays revenue losses of leading pharmaceutical products due to patent expiries in the U.S. from 2014 to 2016. Otsuka's Abilify's U.S. patent will expire in April 2015 and its revenue is expected to drop from almost 3.8 billion U.S. dollars in 2014 down to 334 million U.S. dollars in 2016.

Revenue losses of leading pharmaceutical products due to patent expiries in the U.S. from 2014 to 2016 (in million U.S. dollars)

© Statista 2023
Download
Show detailed source information?
Register for free
Already a member?
Log in
Source

Use Ask Statista Research Service

Release date

December 2014

Region

United States

Survey time period

December 2014

Open this statistic in...
Spanish
Citation formats
Statista Accounts: Access All Statistics. Starting from $1,788 USD / Year
Basic Account
Get to know the platform

You only have access to basic statistics.
This statistic is not included in your account.

Starter Account
The ideal entry-level account for individual users
  • Instant access to 1m statistics
  • Download in XLS, PDF & PNG format
  • Detailed references
$189 USD $149 USD / Month *
in the first 12 months
Professional Account
Full access

Business Solutions including all features.

* Prices do not include sales tax.

Statistics on " Pharmaceutical brands: Abilify (BMS/Otsuka) "

The most important statistics
The most important statistics
The most important statistics

Other statistics that may interest you Pharmaceutical brands: Abilify (BMS/Otsuka)

Overview

5

Drug prices and consumer behavior

2

Advertising expenditures

3

Further related statistics

16

Further Content: You might find this interesting as well

Statistics

Topics

U.S. patentsIntellectual property worldwide
Statista Accounts: Access All Statistics. Starting from $1,788 USD / Year
Learn more about how Statista can support your business.
Menu